4D Molecular Therapeutics Inc (FDMT) - Total Liabilities
Based on the latest financial reports, 4D Molecular Therapeutics Inc (FDMT) has total liabilities worth $61.05 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore FDMT long-term investment intensity to see how much of total assets are deployed in long-term investments.
4D Molecular Therapeutics Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how 4D Molecular Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of 4D Molecular Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Singaraja Putra
JK:SINI
|
Indonesia | Rp2.05 Trillion |
|
Veradigm Inc.
NASDAQ:MDRX
|
USA | $513.64 Million |
|
Solid Power Inc
NASDAQ:SLDP
|
USA | $25.32 Million |
|
Anhui Jiuhuashan Tourism Dvlp
SHG:603199
|
China | CN¥297.59 Million |
|
Lu Thai Textile Co Ltd
SHE:000726
|
China | CN¥4.10 Billion |
|
Zhuhai Zhongfu Enterprise Co Ltd
SHE:000659
|
China | CN¥1.94 Billion |
|
ZRP Printing Group Co. Ltd.
SHE:301223
|
China | CN¥1.43 Billion |
|
BGRIMM Science and Technology Co Ltd
SHG:600980
|
China | CN¥1.47 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down 4D Molecular Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 4D Molecular Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 4D Molecular Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 4D Molecular Therapeutics Inc (2017–2025)
The table below shows the annual total liabilities of 4D Molecular Therapeutics Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $61.05 Million | +22.64% |
| 2024-12-31 | $49.78 Million | +55.26% |
| 2023-12-31 | $32.06 Million | +5.09% |
| 2022-12-31 | $30.51 Million | -11.26% |
| 2021-12-31 | $34.38 Million | +7.63% |
| 2020-12-31 | $31.94 Million | -75.65% |
| 2019-12-31 | $131.20 Million | +5.34% |
| 2018-12-31 | $124.56 Million | +165.52% |
| 2017-12-31 | $46.91 Million | -- |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production o… Read more